Rhythm Pharmaceuticals Acquires Rights to Develop Investigational Therapy RM-853
Rhythm Pharmaceuticals has acquired the rights to develop and commercialize RM-853, an investigational therapy currently in preclinical research for Prader-Willi syndrome (PWS). RM-853, formerly known as T-3525770, is a potent oral inhibitor of ghrelin o-acyltransferase (GOAT), the key enzyme involved in the body’s production of the active form of ghrelin,…